Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar

Citius Oncology Inc. (NASDAQ:CTOR) is one of the most undervalued penny stocks to buy right now. On February 11, Citius Oncology entered into an exclusive distribution agreement with Uniphar to expand the availability of its oncology treatment, LYMPHIR, throughout Western and Eastern Europe. This partnership marked Citius Oncology’s third major international agreement, following similar arrangements in the Middle East, Turkey, and Southern Europe.

Under the terms, Uniphar will manage market access and distribution through country-specific managed access programs. While LYMPHIR is currently FDA-approved in the US, it has not yet received commercial marketing authorization in Europe; therefore, it will be provided solely to patients with relapsed or refractory cutaneous T-cell lymphoma/CTCL who have limited treatment options under local legal frameworks.

LYMPHIR is a targeted immunotherapy designed specifically for patients with Stage I-III CTCL who have already undergone at least one systemic therapy. The drug functions as a recombinant fusion protein that combines an IL-2 receptor binding domain with diphtheria toxin fragments to selectively identify and destroy cancerous T-cells. By inhibiting protein synthesis within these targeted cells, LYMPHIR induces cell death and depletes immunosuppressive regulatory T-cells.

Citius Oncology Inc. (NASDAQ:CTOR) develops and commercializes innovative targeted oncology therapies. It also develops LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

While we acknowledge the potential of CTOR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.